HRT Associated with Lower Dementia Risk, Study Finds
New analyses of UK Biobank data across tens of thousands of postmenopausal women find hormone replacement therapy (HRT) is associated with a reduced risk of dementia, with stronger protection when started in midlife and for those who had surgical menopause. The largest study to date reports about a 16% lower risk of any dementia and a 10% lower risk of Alzheimer's among HRT users, with even greater risk reductions (around 26%) for women who underwent surgical menopause. Researchers emphasize a critical window—roughly the 46–56 age range—during which initiation yields the greatest benefit, while starting outside this window may offer less or no protection. Subgroups such as APOE4 carriers and women with naturally lower lifetime estrogen exposure appear to derive more benefit, underscoring the influence of genetics and hormonal history. These findings echo a shift away from earlier caution following the WHI trials, suggesting potential brain benefits when HRT is timed appropriately, though debates about risks remain in broader contexts. The studies note limitations of observational designs and advise individualized assessment of risks and benefits based on menopause type and personal factors.



